This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro and Sabrina Tavernise. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at nytimes.com/audioapp
Ozempic for All?
Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.
Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.
Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.
Background reading:
- How Ozempic’s maker lost its shine after creating a wonder drug.
- What Trump’s new drug pricing deal means for people with obesity.
Photo: Sergei Gapon/Agence France-Presse — Getty Images
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.